Literature DB >> 3051508

Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis.

G Ricevuti1, A Mazzone, E Uccelli, G Gazzani, G B Fregnan.   

Abstract

Twenty four patients with acute infective exacerbations of chronic bronchitis received amoxycillin alone or in combination with erdosteine (a mucolytic agent) for a week in a double blind, placebo controlled study. Clinical assessment scores, body temperature, serum and sputum amoxycillin concentrations, and sputum culture results were recorded in each group. Erdosteine significantly increased antibiotic concentrations in sputum but not in serum. The combined treatment also caused a more rapid decrease in sputum viscosity and in body temperature and faster sterilisation of the sputum. These results show that erdosteine increases amoxycillin concentration in sputum in patients with acute exacerbations of chronic bronchitis. This effect may be due to a reduction in the viscosity of the bronchial secretions produced by erdosteine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3051508      PMCID: PMC461392          DOI: 10.1136/thx.43.8.585

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  9 in total

1.  N.A.C. AND ANTIBIOTICS IN CYSTIC FIBROSIS.

Authors:  D LAWSON; B A SAGGERS
Journal:  Br Med J       Date:  1965-01-30

2.  The effects of bromhexine on oxytetracycline penetrance into sputum.

Authors:  P H Bach; W P Leary
Journal:  S Afr Med J       Date:  1972-10-14

3.  Observation on the problems accompanying antibiotic treatment in bronchitis with recurrent infection.

Authors:  H Buergi; J Regli; T Medici
Journal:  Arzneimittelforschung       Date:  1969-05

4.  [Experimental study of the possible influence of a fluidifying agent (bromhexine) on the penetration of erythromycine into bronchial secretions (author's transl)].

Authors:  E Bergogne-Berezin; J Pierre; P Dournovo
Journal:  Therapie       Date:  1979 Nov-Dec       Impact factor: 2.070

5.  Determination of amoxicillin in body fluids by reversed-phase liquid chromatography coupled with a post-column derivatization procedure.

Authors:  J Carlqvist; D Westerlund
Journal:  J Chromatogr       Date:  1979-11-11

6.  In vitro assessment of combined antibiotic and mucolytic treatment for Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  D P Heaf; G J Webb; D J Matthew
Journal:  Arch Dis Child       Date:  1983-10       Impact factor: 3.791

7.  Tetracycline levels in bronchial secretions.

Authors:  M J Campbell
Journal:  J Clin Pathol       Date:  1970-07       Impact factor: 3.411

8.  DL-S-(2-[N-3-(2-oxo-tetrahydrothienyl)acetamido])-thioglycolic acid: a novel mucolytic agent of the class of homocysteine thiolactone derivatives.

Authors:  M Gobetti; A Pedrazzoli; S Bradamante
Journal:  Farmaco Sci       Date:  1986-01

9.  Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum.

Authors:  P M Mendelman; A L Smith; J Levy; A Weber; B Ramsey; R L Davis
Journal:  Am Rev Respir Dis       Date:  1985-10
  9 in total
  6 in total

1.  Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in chronic obstructive lung disease.

Authors:  C F Marchioni; M Moretti; M Muratori; M C Casadei; P Guerzoni; R Scuri; G B Fregnan
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 2.  Erdosteine.

Authors:  K L Dechant; S Noble
Journal:  Drugs       Date:  1996-12       Impact factor: 9.546

3.  Erdosteine against acetaminophen induced renal toxicity.

Authors:  Bunyamin Isik; Reyhan Bayrak; Ali Akcay; Sadik Sogut
Journal:  Mol Cell Biochem       Date:  2006-03-11       Impact factor: 3.396

4.  Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344].

Authors:  Peter N Black; Althea Morgan-Day; Tracey E McMillan; Phillippa J Poole; Robert P Young
Journal:  BMC Pulm Med       Date:  2004-12-06       Impact factor: 3.317

5.  The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset.

Authors:  Peter M A Calverley; Alberto Papi; Clive Page; Paola Rogliani; Roberto W Dal Negro; Mario Cazzola; Arrigo F Cicero; Jadwiga A Wedzicha
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-08-22

6.  Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD.

Authors:  Maurizio Moretti; Stefano Fagnani
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-10-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.